vs
Side-by-side financial comparison of CHAMPIONS ONCOLOGY, INC. (CSBR) and Local Bounti Corporation (LOCL). Click either name above to swap in a different company.
CHAMPIONS ONCOLOGY, INC. is the larger business by last-quarter revenue ($15.0M vs $12.5M, roughly 1.2× Local Bounti Corporation). CHAMPIONS ONCOLOGY, INC. runs the higher net margin — 1.8% vs -69.8%, a 71.6% gap on every dollar of revenue. On growth, Local Bounti Corporation posted the faster year-over-year revenue change (23.7% vs 11.5%). CHAMPIONS ONCOLOGY, INC. produced more free cash flow last quarter ($-2.0M vs $-3.6M). Over the past eight quarters, Local Bounti Corporation's revenue compounded faster (21.9% CAGR vs 11.8%).
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Local Bounti Corporation is a U.S.-based sustainable indoor agriculture firm growing fresh, pesticide-free leafy greens, herbs and produce via advanced hydroponic and vertical farming tech. It serves North American retail and food service partners, focusing on low environmental impact and stable year-round supply.
CSBR vs LOCL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.0M | $12.5M |
| Net Profit | $268.0K | $-8.7M |
| Gross Margin | 51.7% | 12.2% |
| Operating Margin | 1.2% | -106.1% |
| Net Margin | 1.8% | -69.8% |
| Revenue YoY | 11.5% | 23.7% |
| Net Profit YoY | -63.2% | 76.0% |
| EPS (diluted) | $0.02 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.0M | $12.5M | ||
| Q3 25 | $14.0M | $12.2M | ||
| Q2 25 | $12.4M | $12.1M | ||
| Q1 25 | $17.0M | $11.6M | ||
| Q4 24 | $13.5M | $10.1M | ||
| Q3 24 | $14.1M | $10.2M | ||
| Q2 24 | $14.0M | $9.4M | ||
| Q1 24 | $12.0M | $8.4M |
| Q4 25 | $268.0K | $-8.7M | ||
| Q3 25 | $-436.0K | $-26.4M | ||
| Q2 25 | $-1.8M | $-21.6M | ||
| Q1 25 | $4.5M | $-37.7M | ||
| Q4 24 | $728.0K | $-36.3M | ||
| Q3 24 | $1.3M | $-34.3M | ||
| Q2 24 | $-109.0K | $-25.3M | ||
| Q1 24 | $-2.5M | $-24.1M |
| Q4 25 | 51.7% | 12.2% | ||
| Q3 25 | 42.9% | 11.5% | ||
| Q2 25 | 41.1% | 12.2% | ||
| Q1 25 | 61.2% | 12.6% | ||
| Q4 24 | 44.9% | 5.4% | ||
| Q3 24 | 49.7% | 13.8% | ||
| Q2 24 | 48.2% | 14.3% | ||
| Q1 24 | 34.7% | 9.4% |
| Q4 25 | 1.2% | -106.1% | ||
| Q3 25 | -3.8% | -149.4% | ||
| Q2 25 | -16.2% | -127.7% | ||
| Q1 25 | 26.4% | -135.6% | ||
| Q4 24 | 5.4% | -166.6% | ||
| Q3 24 | 9.5% | -176.0% | ||
| Q2 24 | -1.9% | -146.8% | ||
| Q1 24 | -21.4% | -122.9% |
| Q4 25 | 1.8% | -69.8% | ||
| Q3 25 | -3.1% | -216.6% | ||
| Q2 25 | -14.9% | -178.3% | ||
| Q1 25 | 26.4% | -324.6% | ||
| Q4 24 | 5.4% | -360.1% | ||
| Q3 24 | 9.3% | -335.2% | ||
| Q2 24 | -0.8% | -267.6% | ||
| Q1 24 | -21.1% | -286.9% |
| Q4 25 | $0.02 | $1.52 | ||
| Q3 25 | $-0.03 | $-1.18 | ||
| Q2 25 | $-0.12 | $-1.63 | ||
| Q1 25 | $0.31 | $-4.32 | ||
| Q4 24 | $0.05 | $-4.24 | ||
| Q3 24 | $0.09 | $-4.01 | ||
| Q2 24 | $-0.01 | $-3.00 | ||
| Q1 24 | $-0.19 | $-2.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.5M | $4.2M |
| Total DebtLower is stronger | — | $483.1M |
| Stockholders' EquityBook value | $4.2M | $-166.2M |
| Total Assets | $30.2M | $410.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.5M | $4.2M | ||
| Q3 25 | $10.3M | $6.2M | ||
| Q2 25 | $9.8M | $5.3M | ||
| Q1 25 | $3.2M | $18.0M | ||
| Q4 24 | $2.8M | $937.0K | ||
| Q3 24 | $2.9M | $317.0K | ||
| Q2 24 | $2.6M | $9.7M | ||
| Q1 24 | $4.5M | $8.2M |
| Q4 25 | — | $483.1M | ||
| Q3 25 | — | $484.9M | ||
| Q2 25 | — | $478.3M | ||
| Q1 25 | — | $480.0M | ||
| Q4 24 | — | $436.8M | ||
| Q3 24 | — | $398.4M | ||
| Q2 24 | — | $374.0M | ||
| Q1 24 | — | $329.8M |
| Q4 25 | $4.2M | $-166.2M | ||
| Q3 25 | $3.5M | $-158.1M | ||
| Q2 25 | $3.8M | $-132.7M | ||
| Q1 25 | $5.5M | $-134.5M | ||
| Q4 24 | $681.0K | $-100.5M | ||
| Q3 24 | $-332.0K | $-65.6M | ||
| Q2 24 | $-1.9M | $-32.8M | ||
| Q1 24 | $-2.1M | $-9.4M |
| Q4 25 | $30.2M | $410.5M | ||
| Q3 25 | $30.5M | $417.8M | ||
| Q2 25 | $32.3M | $426.8M | ||
| Q1 25 | $30.6M | $447.2M | ||
| Q4 24 | $25.2M | $428.0M | ||
| Q3 24 | $24.9M | $430.8M | ||
| Q2 24 | $26.1M | $438.1M | ||
| Q1 24 | $26.8M | $413.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.7M | $-3.1M |
| Free Cash FlowOCF − Capex | $-2.0M | $-3.6M |
| FCF MarginFCF / Revenue | -13.1% | -29.1% |
| Capex IntensityCapex / Revenue | 1.6% | 3.9% |
| Cash ConversionOCF / Net Profit | -6.47× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.6M | $-42.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-1.7M | $-3.1M | ||
| Q3 25 | $600.0K | $-8.9M | ||
| Q2 25 | $6.9M | $-8.7M | ||
| Q1 25 | $490.0K | $-9.6M | ||
| Q4 24 | $-283.0K | $1.2M | ||
| Q3 24 | $311.0K | $-17.2M | ||
| Q2 24 | $-1.8M | $-4.0M | ||
| Q1 24 | $-919.0K | $-7.1M |
| Q4 25 | $-2.0M | $-3.6M | ||
| Q3 25 | $554.0K | $-10.1M | ||
| Q2 25 | $6.6M | $-14.6M | ||
| Q1 25 | $448.0K | $-14.5M | ||
| Q4 24 | $-377.0K | $-8.6M | ||
| Q3 24 | — | $-30.0M | ||
| Q2 24 | $-1.8M | $-28.8M | ||
| Q1 24 | $-1.0M | $-42.1M |
| Q4 25 | -13.1% | -29.1% | ||
| Q3 25 | 4.0% | -82.8% | ||
| Q2 25 | 53.5% | -121.0% | ||
| Q1 25 | 2.6% | -125.1% | ||
| Q4 24 | -2.8% | -85.3% | ||
| Q3 24 | — | -293.1% | ||
| Q2 24 | -13.0% | -305.4% | ||
| Q1 24 | -8.4% | -501.8% |
| Q4 25 | 1.6% | 3.9% | ||
| Q3 25 | 0.3% | 9.7% | ||
| Q2 25 | 2.0% | 48.9% | ||
| Q1 25 | 0.2% | 42.8% | ||
| Q4 24 | 0.7% | 97.6% | ||
| Q3 24 | 0.0% | 125.0% | ||
| Q2 24 | 0.0% | 263.0% | ||
| Q1 24 | 0.8% | 417.3% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
LOCL
Segment breakdown not available.
